Fact CheckerSign in

NCT05838781Completed

DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation

Source: ClinicalTrials.gov · Last updated 22 May 2024

Brief summary (registry, in English)

Atrial fibrillation (AF) is the most common clinical arrhythmia and the prevalence increases with age. AF increases the risk of ischaemic stroke fivefold and accounts for almost one-third of all strokes. As AF is often asymptomatic there are many undetected cases. It is important to find patients with AF and additional risk factors for stroke in order to initiate oral anticoagulation treatment, which can reduce the risk of an ischaemic stroke by 60-70%. Screening is recommended in European guidelines, however the most suitable population and the most suitable device for AF detection remain to be defined. The main objective of this study is to test the hypothesis that AF screening with 14-days continuous ECG monitoring in high-risk individuals identified with a risk prediction model is more effective than routine care in identifying patients with undetected AF. Effectively detecting AF among patients with risk factors for ischaemic stroke has the potential to decrease mortality and morbidity, stroke burden and costs for the society as a whole.

Status (registry)
Completed
Study type
Interventional
Enrollment
2112 (actual)
First submitted
20 Apr 2023
Start date
4 Dec 2023
Primary completion date
16 May 2024
Lead sponsor
Bristol-Myers Squibb
NCT number
NCT05838781

What you commit to

  • Study type: Interventional
  • Participants enrolled: 2112
  • From 4 Dec 2023 to the primary completion date, 16 May 2024
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Dementia
  • Other indication for OAC treatment (such as VTE, mechanical heart valve replacement, VTE prophylaxis post surgery, mitral stenosis, left side intracardial thrombus)

Other

  • Known atrial fibrillation
  • Death
  • No longer resident in Region Halland
  • Pacemaker, implantable cardioverter defibrillator or insertable monitor

Who the study is looking for

  • Alive residents in the Halland region aged 65 or older without a recorded diagnosis of AF

Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Karolinska Institutet Danderyd University Hospital
Coordinator of this site? Confirm its status
StockholmSwedenUnknown status
Halland Hospital Varberg
Coordinator of this site? Confirm its status
VarbergSwedenUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.